Given the association between EBV and MS, we were interested in examining whether MS patients had a detectable CD8+ cell-response to the HLA-E/BZLF1 peptide derived from the BZLF-139–47[47], which has been shown to be recognized by a CD8+ T-cell clone [48]. This evidence concerns the gene HLA-E and myeloid sarcoma.